The delta subunit of the GABA receptor is necessary for the GPT2-promoted breast cancer metastasis.

Glutamic pyruvate transaminase (GPT2) catalyzes the reversible transamination between alanine and α-ketoglutarate (α-KG) to generate pyruvate and glutamate during cellular glutamine catabolism. The glutamate could be further converted to γ-aminobutyric acid (GABA). However, the role of GPT2 in tumor metastasis remains unclear. The wound healing and transwell assays were carried out to analyze breast cancer cell migration and invasion . Gene ontology analysis was utilized following RNA-sequencing to discover the associated molecule function. The mass spectrometry analysis following phosphoprotein enrichment was performed to discover the associated transcription factors. Most importantly, both the tail vein model and Mammary gland conditional spontaneous tumor mouse models were used to evaluate the effect of GPT2 on breast cancer metastasis . GPT2 overexpression increases the content of GABA and promotes breast cancer metastasis by activating GABA receptors. The delta subunit GABRD is necessary for the GPT2/GABA-induced breast cancer metastasis in xenograft and transgenic mouse models. knockout reduces the lung metastasis of the genetic breast cancer in mice and prolongs the overall survival of tumor burden mice. Mechanistically, GPT2-induced GABA receptor activation increases Ca influx by turning on its associated calcium channel, and the surged intracellular calcium triggers the PKC-CREB pathway activation. The activated transcription factor CREB accelerates breast cancer metastasis by upregulating metastasis-related gene expressions, such as PODXL, MMP3, and MMP9. In summary, this study demonstrates that GPT2 promotes breast cancer metastasis through up-regulated GABA activation of GABAR-PKC-CREB signaling, suggesting it is a potential target for breast cancer therapy.